Abstract
Dysfunctioning of corticotropin-releasing factor (CRF) and its receptors (CRF1 and CRF2) has been linked to the development of stress-related disorders, such as affective disorders and drug abuse. The molecular characterization of CRF1 and CRF2 receptors and their splice variants has generated detailed information on their pharmacology, tissue distribution and physiology. In addition, the recent development of a small molecule CRF1 antagonist has provided important information on the contribution of this receptor to the development of stress-related diseases. Despite the high homology to the CRF1 receptor and the generation of peptide-based research tools, the physiological role of the CRF2 receptor is largely unclear. This is due to different expression patterns in rodents and primates and the lack of brainpenetrant CRF2-selective small molecule antagonists. However, the CRF2 receptor may be important for motivational types of behavior essential for survival, such as feeding and defense and impacts on cardiovascular function.
Keywords: stress-related disorders, drug abuse, depression, anxiety, CRF2, CRF1
CNS & Neurological Disorders - Drug Targets
Title: Corticotropin-Releasing Factor Receptor Antagonists in Affective Disorders and Drug Dependence - An Update
Volume: 5 Issue: 2
Author(s): Frank M. Dautzenberg and Thomas Steckler
Affiliation:
Keywords: stress-related disorders, drug abuse, depression, anxiety, CRF2, CRF1
Abstract: Dysfunctioning of corticotropin-releasing factor (CRF) and its receptors (CRF1 and CRF2) has been linked to the development of stress-related disorders, such as affective disorders and drug abuse. The molecular characterization of CRF1 and CRF2 receptors and their splice variants has generated detailed information on their pharmacology, tissue distribution and physiology. In addition, the recent development of a small molecule CRF1 antagonist has provided important information on the contribution of this receptor to the development of stress-related diseases. Despite the high homology to the CRF1 receptor and the generation of peptide-based research tools, the physiological role of the CRF2 receptor is largely unclear. This is due to different expression patterns in rodents and primates and the lack of brainpenetrant CRF2-selective small molecule antagonists. However, the CRF2 receptor may be important for motivational types of behavior essential for survival, such as feeding and defense and impacts on cardiovascular function.
Export Options
About this article
Cite this article as:
Dautzenberg M. Frank and Steckler Thomas, Corticotropin-Releasing Factor Receptor Antagonists in Affective Disorders and Drug Dependence - An Update, CNS & Neurological Disorders - Drug Targets 2006; 5 (2) . https://dx.doi.org/10.2174/187152706776359619
DOI https://dx.doi.org/10.2174/187152706776359619 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Novel Strategies for the Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Enantioresolution of Chiral Derivatives of Xanthones on Different Types of Liquid Chromatography Stationary Phases: A Comparative Study
Current Chromatography Ghrelin and Cardiovascular Diseases
Current Cardiology Reviews New Therapies in SLE
Recent Patents on Inflammation & Allergy Drug Discovery Treatment of the Cheyne-Stokes Breathing Pattern in Patients with Congestive Heart Failure: An Update
Current Respiratory Medicine Reviews From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews Seeds as a Production System for Molecular Pharming Applications: Status and Prospects
Current Pharmaceutical Design Chemistry and Structural Evaluation of Different Phospholipase A2 Inhibitors in Arachidonic Acid Pathway Mediated Inflammation and Snake Venom Toxicity
Current Topics in Medicinal Chemistry Snake Venom Phospholipase A2 Inhibitors: Medicinal Chemistry and Therapeutic Potential
Current Topics in Medicinal Chemistry Association of Posture Instability with Dopamine Drop of Nigrostriatal System and Hypometabolism of Cerebral Cortex in Parkinson’s Disease
Current Neurovascular Research Monoclonal Antibodies in Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry Tachykinins and the Cardiovascular System
Current Drug Targets Chemical and Clinical Development of Darinaparsin, a Novel Organic Arsenic Derivative
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Properties of Mushrooms in Managing Adverse Effects in the Metabolic Syndrome
Current Topics in Medicinal Chemistry Peripartum Cardiomyopathy: An Intriguing Challenge. Case Report with Literature Review
Current Cardiology Reviews Tailoring NO Donors Metallopharmaceuticals: Ruthenium Nitrosyl Ammines and Aliphatic Tetraazamacrocycles
Current Medicinal Chemistry Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging
Anti-Cancer Agents in Medicinal Chemistry